Abstract 3869
Background
Children and adolescents with cancer are at risk of experiencing distress in relation to their cancer diagnosis, treatment and treatment-related procedures. Complementary therapies such as reflexology may be used to help alleviate distressing symptoms; however, there is a dearth of research regarding the experience of reflexology from the perspective of children/adolescents with cancer and/or the parents/guardians of those who have received these treatments. Objective: To ascertain the perceptions of parents/guardians regarding their child/adolescent’s experience of reflexology or non-specific foot massage.
Methods
Children and adolescents aged between 7 and 18 years attending a national children’s hospital for cancer treatment were invited to participate in a randomised controlled trial using a Mixed Between Group Repeated Measures design following receipt of ethical approval from the hospital’s Research Ethics Committee. In total, 75 children/adolescents either consented or assented to take part in the study. Of these, 39 were randomized to the intervention group (reflexology) and 36 to the control group (non-specific foot massage). Semi-structured interviews were undertaken with parents/guardians using an interview guide. Interviews were analysed using Braun and Clarke’s (2006) thematic analysis.
Results
The overarching theme which emerged across the interviews was participants’ perceptions of the foot treatments in general as a means of supporting the child during treatment for cancer. This central theme is discussed under a number of subthemes, namely psychological wellbeing, perceived physiological impact, time and space, a safe relationship and service development.
Conclusions
The parents/guardians views regarding the foot treatments in general were consistently positive. The implications of the study findings and the future delivery of the complementary therapy service will be discussed.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
UCD.
Funding
Childhood Cancer Foundation.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5705 - External validation and longitudinal extension of the LIPI (Lung Immune Prognostic Index) for immunotherapy outcomes in advanced non-small cell lung cancer.
Presenter: Jakob Riedl
Session: Poster Display session 3
Resources:
Abstract
5758 - Changes of TCR Repertoire in Metastatic Renal Cell Carcinoma and Metastatic Melanoma Patients Treated with Nivolumab
Presenter: Martin Klabusay
Session: Poster Display session 3
Resources:
Abstract
1743 - Expression of MHC class I, HLA-A and HLA-B identifies immune activated breast tumors with favorable outcome
Presenter: María Del Mar Noblejas López
Session: Poster Display session 3
Resources:
Abstract
2219 - Prognostic Significance of Tumor Tissue NeuGcGM3 Ganglioside Expression and Predictive Value of Circulating Tumor Cell Count Monitoring in Patients Receiving Racotumomab Immunotherapy
Presenter: Necdet Üskent
Session: Poster Display session 3
Resources:
Abstract
2996 - Evolution of Myeloid-Derived Suppressor Cells and Objective Response Rate in Relapsed/Refractory Diffuse Large B Cell Lymphoma (R/R DLBCL) patients after receiving immunotherapy
Presenter: Carlos Jiménez Cortegana
Session: Poster Display session 3
Resources:
Abstract
2110 - A Phase Ia/Ib trial of the anti-programmed death-ligand 1 (PD-L1) human monoclonal antibody (mAb), CS1001, in patients (pts) with advanced solid tumors or lymphomas
Presenter: Lin Shen
Session: Poster Display session 3
Resources:
Abstract
3515 - Results from a randomised Phase 1/2 trial evaluating the safety and antitumour activity of anti-PD-1 (MEDI0680)/anti-PD-L1 (durvalumab) vs anti-PD-1 (nivolumab) alone in metastatic clear cell renal cell carcinoma (ccRCC)
Presenter: Martin Voss
Session: Poster Display session 3
Resources:
Abstract
3566 - Pembrolizumab in Advanced Rare Cancers
Presenter: Aung Naing
Session: Poster Display session 3
Resources:
Abstract
3567 - High clinical benefit rates of pembrolizumab in very rare sarcoma histotypes: first results of the AcSé Pembrolizumab study
Presenter: Jean-Yves Blay
Session: Poster Display session 3
Resources:
Abstract
2421 - Lenvatinib plus PD-1 blockade in advanced bile tract carcinoma.
Presenter: Jianzhen Lin
Session: Poster Display session 3
Resources:
Abstract